Partnership to Commercialize Prescription Digital Therapeutics in Asia

Happify Health has entered into a deal with Zuellig Pharma to commercialize two of its digital therapeutics solutions. The two solutions are aimed to improve the health outcomes for people with mental health conditions and sleep disorders. One solution, Ensemble, which requires a prescription and teaches people new skills and habits to have better control of their symptoms of Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD) or both. The other solution is similar to Ensemble and is used to treat chronic insomnia that includes features based on the principles of Cognitive Behavioral Therapy (CBT). Murray Zucker, MD, Chief Medical Officer at Happify Health commented that there is a need for early diagnosis for poor mental health as it is associated with higher rates of chronic health problems and treatment which can be provided at scale using digital therapies. Louis Payet, Had of M&A and Digital Therapeutics lead at Zuellig Pharma mentioned in the release that they were impressed with Happify Health and believed their new solutions would positively impact patients by providing access to these therapeutics across the region.

Read more about this news release here.